Association between Increased Serum Osteoprotegerin Levels and Improvement in Bone Mineral Density after Parathyroidectomy in Hemodialysis Patients

この論文にアクセスする

この論文をさがす

著者

    • ZHENG Cai-Mei
    • Division of Nephrology, Department of Medicine, Taipei Medical University-Shuang Ho Hospital, Taipei Medical University
    • CHU Pauling
    • Division of Nephrology, Department of Medicine, Tri-Service General Hospital, National Defense Medical Center
    • WU Chia-Chao
    • Division of Nephrology, Department of Medicine, Tri-Service General Hospital, National Defense Medical Center
    • MA Wen-Ya
    • Department of Medicine, Cardinal Tien Hospital, School of Medicine, Fu-Jen Catholic University
    • HUNG Kuo-Chin
    • Department of Medicine, Cardinal Tien Hospital, School of Medicine, Fu-Jen Catholic University
    • HSU Yung-Ho
    • Division of Nephrology, Department of Medicine, Taipei Medical University-Shuang Ho Hospital, Taipei Medical University
    • LIN Yuh-Feng
    • Division of Nephrology, Department of Medicine, Taipei Medical University-Shuang Ho Hospital, Taipei Medical University
    • DIANG Liang-Kuang
    • Division of Nephrology, Department of Medicine, Tri-Service General Hospital, National Defense Medical Center
    • LU Kuo-Cheng
    • Department of Medicine, Cardinal Tien Hospital, School of Medicine, Fu-Jen Catholic University

抄録

Secondary hyperparathyroidism (SHPT) is a common complication in chronic renal disease. Osteoprotegerin (OPG), an extracellular cytokine receptor secreted by osteoblasts, can promote bone formation by inhibiting the function of osteoclasts. Hemodialysis (HD) patients have elevated serum OPG levels. OPG secretion can be suppressed with high parathyroid hormone (PTH) levels. HD patients with refractory SHPT can benefit from parathyroidectomy (PTX) treatment, but the changes of serum OPG, bone turnover markers and bone mineral density (BMD) following PTX in HD patients remain unclear. In this study, patients on maintenance HD who received PTX for refractory SHPT (<i>n</i> = 28) were prospectively followed for 1 year. Serum intact PTH (iPTH), alkaline phosphatase (Alk-P), and OPG were measured serially; BMD was measured pre-PTX and at 1 year after PTX. After PTX, serum iPTH levels reduced profoundly. Serum Alk-P levels increased rapidly, peaking at 2 weeks post-PTX, while serum OPG levels gradually increased at 2 weeks after PTX and peaked at 2 months. BMD improved in both femoral neck (FN; cancellous and cortical bone) and lumbar spine (LS; cancellous bone). Higher baseline iPTH levels were associated with greater FN and LS BMD improvements at one year after PTX. The increment of serum OPG was correlated with the increase in LS BMD, implying that inhibition of osteoclastic bone resorption may improve BMD within the first year after PTX. These findings suggest that PTX removes the suppressive effects of high PTH on OPG secretion, resulting in the increased serum OPG levels that may contribute to BMD improvement.

収録刊行物

  • Tohoku journal of experimental medicine

    Tohoku journal of experimental medicine 226(1), 19-27, 2012-01-01

    東北ジャーナル刊行会

参考文献:  50件中 1-50件 を表示

各種コード

  • NII論文ID(NAID)
    10030196688
  • NII書誌ID(NCID)
    AA00863920
  • 本文言語コード
    ENG
  • 資料種別
    ART
  • ISSN
    00408727
  • データ提供元
    CJP書誌  J-STAGE 
ページトップへ